GSK (GSK) Competitors

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.

Is GSK or NVO more profitable?

Novo Nordisk A/S has a net margin of 34.81% compared to GSK's net margin of 8.13%. Novo Nordisk A/S's return on equity of 84.68% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	8.13%	48.59%	11.11%
Novo Nordisk A/S	34.81%	84.68%	26.29%

Do insiders and institutionals hold more shares of GSK or NVO?

15.7% of GSK shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media refer more to GSK or NVO?

In the previous week, Novo Nordisk A/S had 43 more articles in the media than GSK. MarketBeat recorded 66 mentions for Novo Nordisk A/S and 23 mentions for GSK. GSK's average media sentiment score of 1.09 beat Novo Nordisk A/S's score of 0.55 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	16 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	29 Very Positive mention(s)	9 Positive mention(s)	14 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Positive

Is GSK or NVO a better dividend stock?

GSK pays an annual dividend of $1.68 per share and has a dividend yield of 4.4%. Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. GSK pays out 86.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend.

Does the MarketBeat Community prefer GSK or NVO?

GSK received 390 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. However, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 57.10% of users gave GSK an outperform vote.

Company	Underperform	Outperform
GSK	Outperform Votes 824 57.10%	Underperform Votes 619 42.90%
Novo Nordisk A/S	Outperform Votes 434 61.74%	Underperform Votes 269 38.26%

Do analysts prefer GSK or NVO?

GSK presently has a consensus price target of $40.58, suggesting a potential upside of 5.36%. Novo Nordisk A/S has a consensus price target of $135.00, suggesting a potential upside of 97.97%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.42
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.38

Which has stronger earnings and valuation, GSK or NVO?

Novo Nordisk A/S has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$31.53B	2.52	$3.29B	$1.94	19.85
Novo Nordisk A/S	$303.14B	1.01	$14.64B	$3.38	20.18

Which has more volatility & risk, GSK or NVO?

GSK has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Summary

Novo Nordisk A/S beats GSK on 12 of the 21 factors compared between the two stocks.